A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan

BACKGROUND: Patients with locally advanced or metastatic urothelial carcinoma have limited treatment options and a poor prognosis. The JAVELIN Bladder 100 trial showed that avelumab as first‐line maintenance plus best supportive care significantly prolonged overall survival and progression‐free surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Po‐Jung, Xiao, Ying, Lin, Amy Y., Goh, Connie, Wu, Ethan, Liu, Kevin, Chou, Patrick, Kuo, Kaitlin, Palencia, Roberto, Chang, Jane, Kearney, Mairead, Kapetanakis, Venediktos, Benedict, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598249/
https://www.ncbi.nlm.nih.gov/pubmed/37640556
http://dx.doi.org/10.1002/cnr2.1887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598249/
https://www.ncbi.nlm.nih.gov/pubmed/37640556
http://dx.doi.org/10.1002/cnr2.1887

Ejemplares similares